Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Iterum TherapeuticsITRMF 5-Year ROIIC % is 716.10 as of Dec. 2024. The stock has 4 warning signs investors should review. Among 1,168 Biotechnology companies, Iterum Therapeutics ranks better than 94.78% on this metric.
5-Year Return on Invested Incremental Capital (5-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 5-year.
Iterum Therapeutics's 5-Year ROIIC % for the quarter that ended in Dec. 2024 was 716.10%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Iterum Therapeutics's 5-Year ROIIC % or its related term are showing as below:
ITRMF's 5-Year ROIIC % is ranked better than 94.78% of 1168
companies
in the Biotechnology industry
Industry Median: -11.085
vs ITRMF: 716.10
Iterum Therapeutics (OTCPK:ITRMF) 5-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Iterum Therapeutics 5-Year ROIIC % Related Terms
Iterum Therapeutics 5-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Iterum Therapeutics's 5-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ITRMF vs HEPA, MTNB, VIVS: 5-Year ROIIC % Comparison
For the Biotechnology subindustry, Iterum Therapeutics's 5-Year ROIIC %, along with its competitors' market caps and 5-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Iterum Therapeutics 5-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Iterum Therapeutics's 5-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Iterum Therapeutics's 5-Year ROIIC % falls into.
Iterum Therapeutics's 5-Year ROIIC % for the quarter that ended in Dec. 2024 is calculated as:
5-Year ROIIC %
=
5-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
5-Year Incremental Invested Capital**
=
( -18.696 (Dec. 2024) - -102.021 (Dec. 2019) )
/
( 34.511 (Dec. 2024) - 22.875 (Dec. 2019) )
=
83.325
/
11.636
=
716.10%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 5-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Iterum Therapeutics (ITRMF) has a 5-Year ROIIC % of 716.10 as of Dec. 2024. 5-Year ROIIC % measures the change in earnings as a percentage of change in investment over 5-year. View historical data on Iterum Therapeutics and its competitors. According to the industry distribution chart, Iterum Therapeutics ranks #61 out of 1168 companies in the Biotechnology industry, placing it in the top 5.2%.
Is Iterum Therapeutics' 5-Year ROIIC % too high?
Iterum Therapeutics' current 5-Year ROIIC % is 716.10. Based on the distribution chart, Iterum Therapeutics ranks #61 out of 1168 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers.
How does Iterum Therapeutics' 5-Year ROIIC % compare to HEPA and MTNB?
According to the Biotechnology industry distribution chart, Iterum Therapeutics ranks #61 out of 1168 companies for 5-Year ROIIC %. This places Iterum Therapeutics in the top 5% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year ROIIC % for a Biotechnology company?
A good 5-Year ROIIC % depends on the Biotechnology industry context. However, 5-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year ROIIC % mean?
A high 5-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 5-Year ROIIC % measures the change in earnings as a percentage of change in investment over 5-year. View historical data on Iterum Therapeutics and its competitors. Iterum Therapeutics's current 5-Year ROIIC % is 716.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Iterum Therapeutics stock overvalued right now?
Iterum Therapeutics (ITRMF) has a current 5-Year ROIIC % of 716.10. The current 5-Year ROIIC % is 716.10. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year ROIIC % calculated?
5-Year ROIIC % is calculated from a company's financial statements. For Iterum Therapeutics (ITRMF), the current 5-Year ROIIC % is 716.10 as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ITRMF has been successfully added to your 
